Document Detail


Oncolytic (replication-competent) adenoviruses as anticancer agents.
MedLine Citation:
PMID:  20132057     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: Whilst therapies for neoplasies have advanced tremendously in the last few decades, there is still a need for new anti-cancer treatments. One option is genetically-engineered oncolytic adenovirus (Ad) 'vectors'. These kill cancer cells via the viral replication cycle, and amplify the anti-tumor effect by producing progeny virions able to infect neighboring tumor cells. AREAS COVERED IN THIS REVIEW: We provide a description of basic Ad biology and summarize the literature for oncolytic Ads from 1996 to the present. WHAT THE READER WILL GAIN: An overall view of oncolytic Ads, the merits and drawbacks of the various features of these vectors, and obstacles to further development and future directions for research. TAKE HOME MESSAGE: Ads are attractive for gene therapy because they are relatively innocuous, easy to produce in large quantities, genetically stable, and easy to manipulate. A variety of have been constructed and tested, in pre-clinical and clinical experiments. Oncolytic Ads proved to be remarkably safe; no dose-limiting toxicity was observed in any clinical trial, and the maximum tolerated dose was not reached. At present, the major challenge for researchers is to increase the efficacy of the vectors, and to incorporate oncolytic virotherapy into existing treatment protocols.
Authors:
Karoly Toth; Debanjan Dhar; William S M Wold
Related Documents :
19442337 - Music therapy in adult oncology: research issues.
17144787 - Complementary medicine for depression.
20523337 - Retrospect and prospect of active principles from chinese herbs in the treatment of dem...
16110347 - Multimodal effects of available drugs for ischemic stroke.
17070947 - Biotechnology in south africa.
17411987 - Research residents' choices of academic radiology careers.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  10     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-05     Completed Date:  2010-04-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  353-68     Citation Subset:  IM    
Affiliation:
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri, USA. toth@slu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenoviridae / genetics*
Gene Expression Regulation, Viral
Genetic Vectors
Humans
Neoplasms / therapy*,  virology
Oncolytic Virotherapy*
Transcription, Genetic
Virus Replication

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplan...
Next Document:  The evolving role of dendritic cells in cancer therapy.